ASRT
- Assertio Holdings, Inc.
()
Overview
Company Summary
Assertio Holdings, Inc., formerly known as Depomed, is a specialty pharmaceutical company that focuses on developing, manufacturing, and marketing extended-release oral products for the treatment of various diseases and disorders. The company primarily operates in the United States.
Assertio Holdings specializes in developing therapeutics that address unmet medical needs and improve patient outcomes. Its portfolio of products includes treatments for pain management, neurology, and other central nervous system disorders. These products are developed using advanced drug delivery technologies and formulations that allow for extended-release, meaning the medication is released gradually over a specific period.
The company's flagship product is Gralise, an extended-release tablet formulation of gabapentin indicated for the management of postherpetic neuralgia, a chronic pain condition that follows the healing of shingles. Gralise is a convenient once-daily medication, providing sustained pain relief to patients.
Assertio also offers Zipsor, an orally disintegrating tablet containing diclofenac potassium, which is used for the relief of mild to moderate acute pain in adults. The product has gained popularity for its quick-dissolving formulation, offering fast pain relief for conditions such as migraines and arthritis.
In addition to its current product portfolio, Assertio Holdings actively pursues licensing and acquiring opportunities to expand its therapeutic offerings. The company's strategy revolves around identifying niches within disease areas and utilizing its expertise in extended-release formulations and drug manufacturing to deliver innovative solutions to patients and healthcare providers.
Overall, Assertio Holdings, Inc. focuses on developing and commercializing extended-release oral products that improve patient convenience, compliance, and outcomes in pain management, neurology, and other central nervous system disorders.